NCT04612894 is a Phase 2 clinical trial of Camrelizumab and Apatinib in Thyroid Cancer, sponsored by Fudan University.

Who is sponsoring NCT04612894?

NCT04612894 is sponsored by Fudan University.

What drugs are being tested in NCT04612894?

Interventions in NCT04612894: Camrelizumab and Apatinib, surgery, core needle biopsy.

What condition does NCT04612894 study?

NCT04612894 studies Thyroid Cancer.

Is NCT04612894 still recruiting?

NCT04612894 is currently status unknown. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT04612894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Status unknown Phase 2 Last updated 3 November 2020

What this trial tests

Phase 2 trial testing Camrelizumab and Apatinib in Thyroid Cancer in 31 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
1 December 2022

31 December 2023

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 December 2020
Primary completion	1 December 2022
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Camrelizumab and Apatinib — full drug profile →
surgery
core needle biopsy

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →

Sponsor

Fudan University

Who can join

14 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real-world experience.
Russell M, Gild ML, Wirth LJ, Robinson B, et al · · 2024 · cited 17× · PMID 38488238 · DOI 10.1002/hed.27735
Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Di Molfetta S, Dotto A, Fanciulli G, Florio T, et al · · 2021 · cited 17× · PMID 33935977 · DOI 10.3389/fendo.2021.667784
Immunotherapies for Pediatric Solid Tumors: A Targeted Update.
Gupta A, Cripe TP. · · 2022 · cited 10× · PMID 34822115 · DOI 10.1007/s40272-021-00482-y
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.
Valerio L, Matrone A. · · 2025 · cited 2× · PMID 40061140 · DOI 10.37349/etat.2025.1002291
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388

Verify or expand the search:

Other trials of Camrelizumab and Apatinib

Trials testing the same drug.

NCT04447274 — A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS · Phase 2 · unknown

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04612894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing